PD
BCRX icon

Point72 (DIFC)’s BioCryst Pharmaceuticals BCRX Stock Holding History

Point72 (DIFC)’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$67.5K Buy
+8,889
New +$74K ﹤0.01% 671
2024
Q3 		– Sell
-66,564
Closed -$411K – 1460
2024
Q2 		$411K Buy
66,564
+57,030
+598% +$315K 0.01% 715
2024
Q1 		$48.4K Buy
+9,534
New +$53.6K ﹤0.01% 1203

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 (DIFC)'s BCRX Position: Q3 2025 in Review

Point72 (DIFC) opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2025: 8,889 shares worth $67.5K. The stake represents ﹤0.01% of the portfolio and ranks #671 among its holdings. This is a return to the name: Point72 (DIFC) previously reported a position in BCRX as recently as Q2 2024.

Point72 (DIFC) first reported a position in BCRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $411K in Q2 2024. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.

  • Point72 (DIFC) held 8,889 shares of BioCryst Pharmaceuticals worth $67.5K as of Q3 2025.
  • BioCryst Pharmaceuticals was a new Point72 (DIFC) position in Q3 2025.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Point72 (DIFC)'s portfolio in Q3 2025, its #671 holding.
  • Point72 (DIFC) first reported a position in BioCryst Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Point72 (DIFC)'s BioCryst Pharmaceuticals position peaked at $411K in Q2 2024.
  • 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.

Based on Point72 (DIFC)'s 13F filing for Q3 2025, filed 14 Nov 2025.